{Etokimab: A Deep Investigation into the 2022981-44-6 Immunoglobulin Etokimab, designated by the specific identifier 2022981-44-6, represents a novel immunoglobulin currently undergoing therapeutic evaluation. This https://www.targetmol.com/compound/etokimab